Keyphrases
Mantle Cell Lymphoma
100%
Lymphoma Patients
63%
Diffuse Large B-cell Lymphoma (DLBCL)
53%
Protein Arginine Methyltransferase 5 (PRMT5)
50%
Positron Emission Tomography
49%
Lymphoma Cells
44%
Lymphoma
37%
Non-Hodgkin Lymphoma
37%
Rituximab
36%
Chronic Lymphocytic Leukemia
36%
Aggressive non-Hodgkin Lymphoma
36%
Chemotherapy
30%
Phase II Trial
29%
Frontline Treatment
28%
Ibrutinib
27%
Complete Response
24%
Relapsed or Refractory
24%
Overall Survival
24%
Working Diagnosis
23%
Programmed Death-ligand 1 (PD-L1)
21%
Classical Hodgkin Lymphoma
21%
Follicular Lymphoma
20%
Hodgkin Disease
20%
Relapse-free Survival
19%
Complete Remission
18%
Cyclophosphamide
18%
MALT Lymphoma
18%
Therapeutic Target
18%
Overall Response Rate
18%
Prednisone
17%
B-cell Lymphoma 2 (Bcl-2)
17%
Cutaneous T-cell Lymphoma
17%
Epstein-Barr Virus
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
CD74
16%
Fludarabine
16%
Milatuzumab
16%
Progression-free Survival
16%
Complete Response Rate
15%
B-cell non-Hodgkin Lymphoma (B-NHL)
15%
Alemtuzumab
15%
B-cell Malignancies
15%
FTY720
14%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14%
Phase II Study
14%
Bortezomib
14%
Cytotoxicity
14%
B-cell Lymphoma
14%
B Cells
14%
Treatment Options
14%
Medicine and Dentistry
Mantle Cell Lymphoma
68%
B Cell
63%
Positron Emission Tomography
58%
Non-Hodgkin Lymphoma
56%
Diffuse Large B-Cell Lymphoma
42%
Disease
35%
Chemotherapy
29%
B-Cell Lymphoma
29%
Protein Arginine Methyltransferase 5
29%
Overall Survival
28%
Ibrutinib
27%
B-Cell Chronic Lymphocytic Leukemia
27%
Hodgkin's Lymphoma
26%
Radiation Therapy
25%
Rituximab
23%
Classical Hodgkin Lymphoma
21%
MALT Lymphoma
20%
Fluorodeoxyglucose F 18
19%
In Vitro
19%
Immunity
18%
Lymphoma Cell
16%
Progression Free Survival
16%
Mantle Cell Lymphoma Cell
15%
Milatuzumab
15%
Follicular Lymphoma
15%
Recurrence Free Survival
15%
Survival Rate
14%
Drug Megadose
14%
Cancer
14%
Neoplasm
14%
Lymphoma
12%
Autophagy
12%
Nivolumab
12%
Targeted Therapy
11%
Transducin
11%
Monoclonal Antibody
11%
Computer Assisted Tomography
11%
Prognostic Factor
11%
Cell Death
10%
Bruton Tyrosine Kinase Inhibitor
9%
CHOP
9%
Cutaneous T Cell Lymphoma
9%
Fingolimod
9%
Bortezomib
9%
Autotransplantation
9%
Chimeric Antigen Receptor T-Cell
9%
Cytotoxicity
9%
Synapsin I
9%
Lung
9%
Clinical Trial
8%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
67%
Nonhodgkin Lymphoma
62%
Chemotherapy
37%
Diffuse Large B Cell Lymphoma
34%
Rituximab
31%
Remission
26%
Chronic Lymphatic Leukemia
25%
Overall Survival
24%
Disease
21%
Ibrutinib
21%
Phase II Trials
18%
B Cell Lymphoma
17%
Milatuzumab
15%
Hodgkin Disease
15%
Alemtuzumab
15%
Progression Free Survival
14%
Fingolimod
14%
Cutaneous T Cell Lymphoma
14%
Bortezomib
14%
Monoclonal Antibody
13%
Survival Rate
13%
Bruton Tyrosine Kinase Inhibitor
13%
Acute Myeloid Leukemia
12%
Neoplasm
11%
Epirubicin
11%
Fludarabine
11%
Follicular Lymphoma
11%
Cyclophosphamide
11%
Etoposide
11%
Malignant Neoplasm
10%
Prednisone
9%
T Cell Lymphoma
9%
Cytotoxicity
9%
Clinical Trial
9%
Recurrent Disease
8%
Cyclin D1
8%
Mitoxantrone
7%
Peripheral T Cell Lymphoma
7%
Histone
7%
Toxicity
7%
Ifosfamide
6%
Recurrence Free Survival
6%
Granulocyte Colony Stimulating Factor
6%
Transducin
6%
Disease Exacerbation
6%
Combination Therapy
6%
Drug Resistance
6%
Bruton Tyrosine Kinase
5%
High Dose Chemotherapy
5%
Tegavivint
5%